{"id":"recombinant-human-papillomavirus-bivalent-vaccine","safety":{"commonSideEffects":[{"rate":"70-80","effect":"Injection site pain or soreness"},{"rate":"25-35","effect":"Injection site swelling or erythema"},{"rate":"10-15","effect":"Fever"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The bivalent HPV vaccine contains recombinant viral-like particles (VLPs) derived from the major capsid protein of HPV types 16 and 18, the two most oncogenic HPV strains. Upon administration, these VLPs trigger both humoral and cellular immune responses, generating neutralizing antibodies and T-cell immunity that prevent initial HPV infection and subsequent malignant transformation of cervical epithelial cells.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against two types of human papillomavirus (HPV-16 and HPV-18) to prevent infection and cervical cancer development.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:18.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV-16 and HPV-18"},{"name":"Prevention of cervical intraepithelial neoplasia (CIN) grades 2 and 3"}]},"trialDetails":[{"nctId":"NCT05237947","phase":"PHASE4","title":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":5000},{"nctId":"NCT04537156","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiamen University","startDate":"2020-09-05","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata","enrollment":9327},{"nctId":"NCT02834637","phase":"PHASE3","title":"A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-02-23","conditions":"Human Papilloma Virus","enrollment":930},{"nctId":"NCT03180034","phase":"PHASE4","title":"Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-29","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma","enrollment":27945},{"nctId":"NCT04301154","phase":"PHASE1","title":"Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2022-02-18","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT03728881","phase":"PHASE3","title":"Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":1240},{"nctId":"NCT06243666","phase":"","title":"Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiamen University","startDate":"2024-02-20","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection","enrollment":2188},{"nctId":"NCT01824537","phase":"PHASE4","title":"Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study","status":"COMPLETED","sponsor":"McGill University","startDate":"2014-01","conditions":"Human Papillomavirus Infection","enrollment":372},{"nctId":"NCT04508309","phase":"PHASE3","title":"Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-15","conditions":"Cervical Cancer","enrollment":1025},{"nctId":"NCT06776055","phase":"","title":"Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2023-03-27","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":5372},{"nctId":"NCT06582654","phase":"","title":"Normalizing Antibody Detection in First-void Urine","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2023-12-07","conditions":"Human Papillomavirus Infection","enrollment":150},{"nctId":"NCT03675256","phase":"PHASE4","title":"The KEN SHE Study on HPV-vaccine Efficacy","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2018-12-19","conditions":"Papillomavirus Infections","enrollment":2275},{"nctId":"NCT02710851","phase":"PHASE2","title":"Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2016-03-24","conditions":"Condylomata Acuminata","enrollment":640},{"nctId":"NCT04965350","phase":"PHASE3","title":"Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females","status":"COMPLETED","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2021-04-20","conditions":"HPV Infection","enrollment":1100},{"nctId":"NCT02740790","phase":"PHASE2","title":"Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females","status":"COMPLETED","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2013-09","conditions":"Human Papillomavirus","enrollment":1200},{"nctId":"NCT03671369","phase":"","title":"A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-10-02","conditions":"Neoplasms, Rectal","enrollment":670},{"nctId":"NCT05045755","phase":"","title":"The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-04-13","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":1339},{"nctId":"NCT04704908","phase":"","title":"Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-02-06","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":979},{"nctId":"NCT04969445","phase":"","title":"The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-03-30","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":647},{"nctId":"NCT01914367","phase":"PHASE4","title":"Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2013-06-25","conditions":"Infection With Human Papillomavirus","enrollment":12},{"nctId":"NCT05426148","phase":"PHASE4","title":"Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female","status":"COMPLETED","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2020-05-01","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":540},{"nctId":"NCT05415345","phase":"PHASE4","title":"Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin","status":"UNKNOWN","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2021-10-25","conditions":"Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Hepatitis E Virus Infection","enrollment":480},{"nctId":"NCT02405520","phase":"PHASE1","title":"Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine","status":"COMPLETED","sponsor":"Jun Zhang","startDate":"2015-03-26","conditions":"Condylomata Acuminata","enrollment":145},{"nctId":"NCT05383625","phase":"PHASE3","title":"Gardasil Versus Cervarix in the Treatment of Warts","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-09-01","conditions":"Verruca Viral","enrollment":50},{"nctId":"NCT05279248","phase":"PHASE4","title":"The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2021-08-25","conditions":"Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles","enrollment":300},{"nctId":"NCT02979535","phase":"PHASE3","title":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-16","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease","enrollment":480},{"nctId":"NCT04391647","phase":"","title":"Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2020-05-11","conditions":"Human Papilloma Virus Infection","enrollment":50},{"nctId":"NCT03438006","phase":"","title":"A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-05-31","conditions":"Cervical Intraepithelial Neoplasia","enrollment":3016},{"nctId":"NCT03355820","phase":"PHASE3","title":"A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-02-28","conditions":"Cervical Intraepithelial Neoplasia","enrollment":228},{"nctId":"NCT00481767","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-01","conditions":"Human Papillomavirus (HPV) Infection","enrollment":676},{"nctId":"NCT00947115","phase":"PHASE3","title":"Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-22","conditions":"Infections, Papillomavirus","enrollment":525},{"nctId":"NCT00956553","phase":"PHASE4","title":"Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls","status":"COMPLETED","sponsor":"Public Health England","startDate":"2009-09","conditions":"HPV Infections","enrollment":400},{"nctId":"NCT03105856","phase":"PHASE4","title":"FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2017-01-03","conditions":"Cervical Intraepithelial Neoplasia, HPV-Related Cervical Carcinoma","enrollment":3000},{"nctId":"NCT01031069","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-26","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":873},{"nctId":"NCT01263327","phase":"PHASE1","title":"Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2010-12","conditions":"Cervical Cancer","enrollment":38},{"nctId":"NCT01381575","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-29","conditions":"Infections, Papillomavirus","enrollment":1447},{"nctId":"NCT03747770","phase":"NA","title":"Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2018-12-17","conditions":"Healthy","enrollment":18000},{"nctId":"NCT01627561","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Infections, Papillomavirus","enrollment":148},{"nctId":"NCT01456715","phase":"PHASE3","title":"Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.","status":"COMPLETED","sponsor":"Laval University","startDate":"2008-09","conditions":"Human Papillomavirus","enrollment":418},{"nctId":"NCT01735006","phase":"PHASE3","title":"Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2012-11-22","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":7372},{"nctId":"NCT00877877","phase":"PHASE3","title":"Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-07","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":632},{"nctId":"NCT00637195","phase":"PHASE3","title":"Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-11","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":152},{"nctId":"NCT00586339","phase":"PHASE2","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-17","conditions":"Infections, Papillomavirus","enrollment":150},{"nctId":"NCT00423046","phase":"PHASE3","title":"Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-24","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":1106},{"nctId":"NCT00359619","phase":"PHASE2","title":"Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-12","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":383},{"nctId":"NCT00250276","phase":"PHASE3","title":"Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10-28","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":798},{"nctId":"NCT00294047","phase":"PHASE3","title":"Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-16","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":5752},{"nctId":"NCT00196937","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10-07","conditions":"Infections, Papillomavirus","enrollment":667},{"nctId":"NCT00534638","phase":"PHASE4","title":"Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-04","conditions":"Infections, Papillomavirus","enrollment":34412},{"nctId":"NCT01462357","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-21","conditions":"Infections, Papillomavirus","enrollment":1079},{"nctId":"NCT01249365","phase":"PHASE3","title":"The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-24","conditions":"Infections, Papillomavirus","enrollment":199},{"nctId":"NCT00730847","phase":"PHASE4","title":"A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2008-09-17","conditions":"Human Papillomavirus Infection Leading to Cervical Cancer","enrollment":743},{"nctId":"NCT01190176","phase":"PHASE3","title":"Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-12","conditions":"Infections, Papillomavirus","enrollment":34},{"nctId":"NCT00937950","phase":"PHASE3","title":"Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-05","conditions":"Infections, Papillomavirus","enrollment":2022},{"nctId":"NCT01190189","phase":"PHASE3","title":"Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-01","conditions":"Infections, Papillomavirus","enrollment":137},{"nctId":"NCT00779766","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-22","conditions":"Infections, Papillomavirus","enrollment":6081},{"nctId":"NCT02837926","phase":"PHASE4","title":"Comparing Health Services Interventions for the Prevention of HPV-related Cancer","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2016-05","conditions":"Cervical Cancer","enrollment":63},{"nctId":"NCT02811068","phase":"","title":"Observational Follow up of Prior HPV Vaccinees","status":"COMPLETED","sponsor":"Public Health England","startDate":"2016-12","conditions":"Human Papillomavirus Virus","enrollment":93},{"nctId":"NCT00128661","phase":"PHASE3","title":"Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-30","conditions":"Cervical Cancer, Precancerous Condition","enrollment":7466},{"nctId":"NCT02567955","phase":"PHASE3","title":"Immunogenicity and Safety of Gardasil-9 and Cervarix","status":"COMPLETED","sponsor":"Laval University","startDate":"2015-09","conditions":"HPV Vaccines Immunogenicity and Safety","enrollment":376},{"nctId":"NCT03206255","phase":"","title":"Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls","status":"COMPLETED","sponsor":"Jun Zhang","startDate":"2017-07-01","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":940},{"nctId":"NCT01461993","phase":"PHASE2","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-28","conditions":"Vaccines, Meningococcal Vaccines","enrollment":2499},{"nctId":"NCT02234921","phase":"PHASE1","title":"Pilot Study of DRibble Vaccine for Prostate Cancer Patients","status":"COMPLETED","sponsor":"UbiVac","startDate":"2014-10-24","conditions":"Adenocarcinoma of the Prostate","enrollment":3},{"nctId":"NCT00309166","phase":"PHASE2","title":"Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-05","conditions":"Infections, Papillomavirus","enrollment":270},{"nctId":"NCT00316693","phase":"PHASE2","title":"Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-26","conditions":"Infections, Papillomavirus","enrollment":1046},{"nctId":"NCT00492544","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-02","conditions":"Infections, Papillomavirus","enrollment":100},{"nctId":"NCT01717118","phase":"PHASE4","title":"Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2009-11","conditions":"Healthy","enrollment":2000},{"nctId":"NCT00122681","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05-06","conditions":"Infections, Papillomavirus","enrollment":18729},{"nctId":"NCT00652938","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-09","conditions":"Infections, Papillomavirus","enrollment":744},{"nctId":"NCT00578227","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-15","conditions":"Infections, Papillomavirus","enrollment":814},{"nctId":"NCT00541970","phase":"PHASE1","title":"Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-17","conditions":"Infections, Papillomavirus","enrollment":961},{"nctId":"NCT00996125","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-24","conditions":"Infections, Papillomavirus","enrollment":750},{"nctId":"NCT01277042","phase":"PHASE3","title":"Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-17","conditions":"Infections, Papillomavirus","enrollment":1212},{"nctId":"NCT02562508","phase":"PHASE3","title":"A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls","status":"COMPLETED","sponsor":"Jun Zhang","startDate":"2015-12-05","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia","enrollment":979},{"nctId":"NCT01290393","phase":"","title":"Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-09-26","conditions":"Infections, Papillomavirus","enrollment":2},{"nctId":"NCT01101542","phase":"","title":"Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Papillomavirus","enrollment":3091},{"nctId":"NCT00549900","phase":"PHASE1","title":"A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-02","conditions":"Infections, Papillomavirus","enrollment":30},{"nctId":"NCT00345878","phase":"PHASE3","title":"Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-25","conditions":"Infections, Papillomavirus","enrollment":271},{"nctId":"NCT00485732","phase":"PHASE3","title":"A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-11","conditions":"Infections, Papillomavirus","enrollment":225},{"nctId":"NCT00369824","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-26","conditions":"Infections, Papillomavirus","enrollment":1330},{"nctId":"NCT00344032","phase":"PHASE3","title":"Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-07-28","conditions":"Infections, Papillomavirus","enrollment":354},{"nctId":"NCT00426361","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-13","conditions":"Infections, Papillomavirus","enrollment":751},{"nctId":"NCT00799825","phase":"PHASE3","title":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-01","conditions":"Infections, Papillomavirus","enrollment":346},{"nctId":"NCT01755689","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-11","conditions":"Infections, Meningococcal","enrollment":1300},{"nctId":"NCT00546078","phase":"PHASE2","title":"Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-14","conditions":"Infections, Papillomavirus","enrollment":116},{"nctId":"NCT00552279","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-12","conditions":"Infections, Papillomavirus","enrollment":805},{"nctId":"NCT00815282","phase":"PHASE4","title":"Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease","status":"COMPLETED","sponsor":"N.M. Wulffraat","startDate":"2009-02","conditions":"Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Juvenile Dermatomyositis","enrollment":135},{"nctId":"NCT02714114","phase":"","title":"Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2015-09","conditions":"Human Papilloma Virus Infection","enrollment":57},{"nctId":"NCT00337818","phase":"PHASE3","title":"Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Papillomavirus Type 16/18 Infection, Cervical Intraepithelial Neoplasia","enrollment":770},{"nctId":"NCT00478621","phase":"PHASE1","title":"Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-25","conditions":"Infections, Papillomavirus","enrollment":540},{"nctId":"NCT01953822","phase":"","title":"Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10","conditions":"Infections, Papillomavirus","enrollment":1053},{"nctId":"NCT00456807","phase":"PHASE3","title":"Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Infections, Papillomavirus","enrollment":100},{"nctId":"NCT00518336","phase":"PHASE2","title":"Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":"Infections, Papillomavirus","enrollment":433},{"nctId":"NCT00929526","phase":"PHASE3","title":"Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06","conditions":"Infections, Papillomavirus","enrollment":752},{"nctId":"NCT00811798","phase":"PHASE3","title":"Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Infections, Papillomavirus","enrollment":92},{"nctId":"NCT00689741","phase":"PHASE2","title":"Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-01","conditions":"Infections, Papillomavirus","enrollment":1113},{"nctId":"NCT01356823","phase":"PHASE2","title":"Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2011-03","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer","enrollment":1600},{"nctId":"NCT02276521","phase":"","title":"Evaluation of Long Term Immunity Following HPV Vaccination","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2015-02","conditions":"Cervical Cancer, Anogenital Warts","enrollment":200},{"nctId":"NCT02082639","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-02","conditions":"Infections, Papillomavirus","enrollment":""},{"nctId":"NCT02100618","phase":"PHASE3","title":"Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-01","conditions":"Infections, Papillomavirus","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cervarix","GSK-580299","HPV 16/18 L1 VLP/AS04 VAC","HPV-16/18 VLP/AS04 Vaccine","Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine"],"phase":"marketed","status":"active","brandName":"Recombinant Human Papillomavirus Bivalent Vaccine","genericName":"Recombinant Human Papillomavirus Bivalent Vaccine","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against two types of human papillomavirus (HPV-16 and HPV-18) to prevent infection and cervical cancer development. Used for Prevention of cervical cancer caused by HPV-16 and HPV-18, Prevention of cervical intraepithelial neoplasia (CIN) grades 2 and 3.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}